Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics RegisterEoghan McCarthy, Benjamin Rhodes, Peter Lanyon et al.|Lara D. Veeken|2017Cited by 94
Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre studyKhaled Mahmoud, Edward M Vital, Ahmed S Zayat et al.|Lara D. Veeken|2021Cited by 28
Revision to the musculoskeletal domain of the BILAG-2004 index to incorporate ultrasound findingsRobert D Sandler, Chee‐Seng Yee, Edward M Vital et al.|Lara D. Veeken|2023Cited by 12
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and WalesEoghan McCarthy, Emily Sutton, Stephanie Nesbit et al.|Lara D. Veeken|2017Cited by 4
262 Longitudinal Assessment of Systemic Lupus Erythematosus Disease Activity: British Isles Lupus Assessment Group 2004, Systemic Lupus Erythematosus Disease Activity Index 2000 or Both?Chee‐Seng Yee, Vernon T. Farewell, Caroline Gordon et al.|Lara D. Veeken|2016Cited by 3